OcuLightRx – Advanced LLLT

30 DAY IN-OFFICE FREE TRIAL

Boost Your Practice with OcuLightRx LLLT

The OcuLightRx Low-Level Light Therapy (LLLT) Device can enhance your practice by delivering standalone or complementary dry eye treatment and more, at a fraction of the cost of other devices and offers easy-to-use functionality. 

OcuLightRx offers photobiomodulation (PBM), a non-thermal approach that uses specific light wavelengths to treat many different eye conditions like Dry Eye, MGD, Tear film Stability, Styes, Demodex, and Blepharitis.

Core Features - Medical-Grade, Clinically Proven Wavelengths:

Red Light (630-660nm) - uses wavelengths to stimulate meibomian glands, reduce inflammation, and enhance tear film stability. Many patients report relief after just a few 10-to 15-minute sessions.

Red light therapy targets mitochondrial dysfunction in ocular cells, boosting ATP (energy) production. This enhances the health of cells in the cornea, conjunctiva, and meibomian glands, supporting tissue repair and improving overall ocular surface health. This mechanism is particularly beneficial for addressing the root causes of dry eye.

Blue Light (405-470nm) - is Antimicrobial, reducing the bacterial load on eyelid margins for Meibomian Gland Dysfunction (MGD), and can also treat blepharitis, styes, and demodex.

Near-Infrared Light (850nm) - Using PBM the 850nm wavelengths penetrate deeply into eyelid tissues to stimulate cellular repair, reduce inflammation, and enhance tear production, providing relief for dry eye symptoms. This non-invasive treatment works by boosting mitochondrial energy production (ATP) in meibomian glands and surrounding tissues, improving gland function and lipid layer quality in the tear film. Clinical studies show that 850 nm NIR therapy can increase tear breakup time (TBUT) by 20-30%, reduce ocular surface disease index (OSDI) scores by up to 40%, and promote anti-inflammatory effects, alleviating burning and grittiness.

Studies of Low-Level Light (LLLT) Therapy for Dry Eye:

1. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial
2. A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye
3. Intense Pulse Light Combined With Low-Level Light Therapy in Dry Eye Disease: A Systematic Review

 OcuLightRx built for Eyecare

• Purpose-built for dry eye and meibomian gland dysfunction care.
• Non-thermal photobiomodulation that supports gland function, inflammation control, and tear-film stability.
• Adjustable intensity and treatment duration for individualized protocols.
• Easy to integrate alongside RF, IPL, and diagnostic workflows.
• No consumables and minimal staff burden.

Rapid Return on Investment

• High Revenue: Just 5 weekly treatments at $250 could generate $65,000 annually.
• Upsell Potential: Enhances RF/IPL treatments, increasing per-patient revenue.
• Scalable: Quick 15-20 minute sessions maximize patient experience.

Customizable Treatment Modes

Choose from pre-set programs tailored for specific concerns, or manually adjust intensity and wavelength combinations to suit your needs.

Ergonomic, Portable Design

Lightweight and foldable, its adjustable panels allow for targeted-area treatments. Also has the capability to perform treatments while patient is sitting down.

Smart Timer 

Keep track of your sessions effortlessly with the integrated smart timer.

What’s in the Box?

• OcuLightRx LED Therapy Device
• Adjustable Stand
• Charging Adapter & Cable
• User Manual & Quick Start Guide

Specifications

• Wavelengths: Red (630-660nm), Blue (405-470nm), Near-Infrared (850nm) Yellow (590nm)
• Power Output: Up to 100mW/cm²
• Size: 4ft(h)2ft(w)